Newly obtained Department of Veterans Affairs records have brought intense scrutiny to how the agency diagnoses military veterans with Cannabis Use Disorder. Documents released through Freedom of Information Act requests filed by the Veterans Action Council reveal growing concern that Veterans Health Administration clinicians routinely attach formal psychiatric diagnoses to patients based on little more than a positive drug screen, often bypassing the thorough evaluations required by modern clinical guidelines.
The controversy centers on the friction between federal medical bureaucracy and the psychiatric framework established in the 2013 Diagnostic and Statistical Manual of Mental Disorders. When the DSM-5 collapsed the previous classifications of cannabis abuse and dependence into a single, spectrum-based disorder, it inadvertently cast a far wider diagnostic net. Because the manual does not clearly separate state-authorized, therapeutic use from problematic, compulsive consumption, patients relying on daily cannabis regimens for chronic pain, traumatic brain injury, or combat-related PTSD can easily meet criteria like tolerance or sustained use, even when the substance substantially improves their daily functioning.
Internal agency correspondence underscores the disconnect between medical reality and administrative practice. In 2022, VA data showed roughly 135,000 veterans testing positive for cannabis alongside more than 139,000 diagnosed with Cannabis Use Disorder. This near one-to-one ratio sharply contradicts national epidemiological benchmarks, such as the NESARC-III survey, which indicate that only a small minority of cannabis consumers meet the threshold for a true clinical disorder. Furthermore, internal studies revealed that nearly a third of patient records contained no documented conversation about cannabis between doctors and patients, demonstrating that the label is frequently applied without informing the veteran or evaluating the actual context of their use.
For veterans, the consequences of an unvetted substance use diagnosis are far-reaching and enduring. An erroneous psychiatric entry in a permanent electronic health chart can compromise pain management options, limit access to essential medications, disrupt disability evaluations, and severely damage the patient-provider relationship. While advocates and internal researchers agree that genuine dependency warrants support and intervention, they maintain that laboratory findings must never serve as a shortcut for nuanced clinical judgment, urging the agency to ensure that administrative convenience does not eclipse individualized veteran care.
Dabbin-Dad Newsroom
